Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for $8.00 per share in cash upfront, with an additional $2.00 per share contingent value right tied to VG-3927's first commercial sale.
Vigil Neuroscience is on track to report final analysis from the IGNITE Phase 2 trial of iluzanebart for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in Q2 2025, with plans to pursue accelerated approval.
Vigil Neuroscience reports positive Phase 1 data for VG-3927, an oral TREM2 agonist, showing a favorable safety profile in healthy adults and Alzheimer's patients.